TABLE 4.
HTLV‐1 Tax‐specific CTLs, HTLV‐1 provirus DNA, and TCR repertoire analyses in the peripheral blood samples
| Number of patients | HLA | Tax‐specific CTLs/lymphocyte (%) | Tax‐specific CTL subtype | TCR V beta usage major clones | HTLV‐1 provirus load (copies/1000PBMCs) | Date of examination from starting therapy (months) | ||
|---|---|---|---|---|---|---|---|---|
| Memory (%) | Effector (%) | Naïve (%) | ||||||
| 2 a | A*02:01 | 0.266 | 96.2 | 3.8 | 0.0 |
V beta 14: 60.4% V beta 12: 26.2% V beta 16: 14.0% |
50.2 | 211 |
| 3 | A*02:01 | 0.153 | 83.0 | 5.7 | 9.4 |
V beta 22: 25.0% V beta 2: 15.2% |
12.3 | 177 |
| A*24:02 | 0.011 | N.E. | Not examined | |||||
| 4 | A*02:01 | 0.308 | 95.7 | 1.1 | 3.2 | Not determined | 66.6 | 125 |
| A*24:02 | 0.882 | 61.2 | 0.8 | 38.1 | Not determined | |||
| 7 a | A*02:01 | 0.065 | 96.3 | 0.0 | 3.7 |
V beta 14: 43.6% V beta 3: 13.9% V beta 20: 13.6% V beta 8: 13.0% V beta 21.3: 10.5% |
15.3 | 45 |
| A*24:02 | 0.878 | 99.8 | 0.1 | 0.1 | Not determined | |||
| 8 a | A*24:02 | 0.09 | 90.3 | 0.0 | 9.7 |
V beta 3: 61.1% V beta 12: 18.2% |
137.3 | 39 |
| 9 | A*02:01 | 1.40 | 91.7 | 1.7 | 6.5 | Not determined | 22.2 | 35 |
Abbreviations: CTLs, cytotoxic T lymphocytes; HLA, human leukocyte antigen; HTLV‐1, human T lymphotropic virus type 1; not determined, the usage of TCR V beta genes >10% was not detected in this study; TCR, T‐cell receptor.
a
Patients who experienced herpes virus infection during chemotherapy.